Neurocrine reports a second PhIII success in congenital adrenal hyperplasia, this time in children

Lei Lei Wu

News Reporter

Neurocrine Biosciences said its treatment for congenital adrenal hyperplasia (CAH) — a genetic disorder that causes hormone imbalance — helped reduce the daily dose of steroids that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Neurocrine reports a second PhIII success in congenital adrenal hyperplasia, this time in children

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Breaking down silos with a new quantitative approach to drug development

Neu­ro­crine re­ports a sec­ond PhI­II suc­cess in con­gen­i­tal adren­al hy­per­pla­sia, this time in chil­dren

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Neurocrine reports a second PhIII success in congenital adrenal hyperplasia, this time in children